Vipin K. Garg - 30 Jan 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
President and CEO, Director
Signature
/s/ Richard I. Eisenstadt, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
30 Jan 2024
Net transactions value
-$93,409
Form type
4
Filing time
01 Feb 2024, 18:01:14 UTC
Previous filing
29 Jan 2024
Next filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $0 +26,775 +11% $0.000000 276,030 30 Jan 2024 Direct F1
transaction ALT Common Stock, par value $0.0001 Tax liability $114,631 -11,697 -4.2% $9.80 264,333 30 Jan 2024 Direct F2
transaction ALT Common Stock, par value $0.0001 Award $21,221 +7,889 +3% $2.69 272,222 31 Jan 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Restricted Stock Units Options Exercise $0 -26,775 -25% $0.000000 80,325 30 Jan 2024 Common Stock, par value $0.0001 26,775 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2 Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3 These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024.
F4 In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023.
F5 The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.